Last updated on November 2019

A phase II multi-center, randomized, doubleblind, 24-week, 3-arm, parallel group, placebo-controlled study to investigate the efficacy and safety of RO5285119 in children and adolescents age 5-17 with autism spectrum disorder (ASD)


Brief description of study

A PHASE II MULTI-CENTER, RANDOMIZED, DOUBLEBLIND, 24-WEEK, 3-ARM, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RO5285119 IN CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)

 

Detailed Study Description

CHILDREN AND ADOLESCENTS AGE 5-17 WITH AUTISM SPECTRUM DISORDER (ASD)

 

Clinical Study Identifier: TX144964

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.